FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results